Legal & General Group
PHAS

Legal & General Group’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Legal & General Group’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,745
Closed -$6K – 3726
2021
Q1 		$6K Sell
1,745
-174
-9% -$706 ﹤0.01% 3473
2020
Q4 		$6K Hold
1,919
– – ﹤0.01% 3425
2020
Q3 		$7K Sell
1,919
-850
-31% -$3.42K ﹤0.01% 3352
2020
Q2 		$13K Buy
2,769
+739
+36% +$3.27K ﹤0.01% 3249
2020
Q1 		$7K Sell
2,030
-865
-30% -$3.96K ﹤0.01% 3228
2019
Q4 		$18K Buy
2,895
+612
+27% +$2.52K ﹤0.01% 3216
2019
Q3 		$10K Hold
2,283
– – ﹤0.01% 3272
2019
Q2 		$30K Buy
+2,283
New +$28K ﹤0.01% 3027

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Legal & General Group's PHAS Position: Q2 2021 in Review

Legal & General Group sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2021, closing a stake of 1,745 shares — an estimated $6K sold.

Legal & General Group first reported a position in PHAS in Q2 2019 and held it in 8 quarters. The position peaked at $30K in Q2 2019. 55 funds tracked by Wall St. Rank hold PHAS as of Q2 2021.

  • Legal & General Group reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 1,745 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $6K.
  • Legal & General Group first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
  • Legal & General Group's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $30K in Q2 2019.
  • 55 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.